Background: Previous psychological and pharmacological interventions have primarily focused on depression disorders in populations with cardiovascular diseases (CVDs) and the efficacy of anxiety disorder interventions is only more recently being explored. Transdiagnostic interventions address common emotional processes and the full range of anxiety and depression disorders often observed in populations with CVDs. The aim of CHAMPS is to evaluate the feasibility of a unified protocol (UP) for the transdiagnostic treatment of emotional disorders intervention in patients recently hospitalized for CVDs. The current study reports the protocol of a feasibility randomized controlled trial to inform a future trial.Methods/DesignThis is a feasibility randomized, controlled trial with a single-center design. A total of 50 participants will be block-randomized to either a UP intervention or enhanced usual care. Both groups will receive standard CVD care. The UP intervention consists of 1) enhancing motivation, readiness for change, and treatment engagement; (2) psychoeducation about emotions; (3) increasing present focused emotion awareness; (4) increasing cognitive flexibility; (5) identifying and preventing patterns of emotion avoidance and maladaptive emotion-driven behaviors (EDBs, including tobacco smoking, and alcohol use); (6) increasing tolerance of emotion-related physical sensations; (7) interoceptive and situation-based emotion-focused exposure; and (8) relapse prevention strategies. Treatment duration is 12 to 18 weeks. Relevant outcomes include the standard deviation of self-rated anxiety, depression and quality of life symptoms. Other outcomes include intervention acceptability, satisfaction with care, rates of EDBs, patient adherence, physical activity, cardiac and psychiatric readmissions. Parallel to the main trial, a nonrandomized comparator cohort will be recruited comprising 150 persons scoring below the predetermined depression and anxiety severity thresholds.DiscussionCHAMPS is designed to evaluate the UP for the transdiagnostic treatment of emotional disorders targeting emotional disorder processes in a CVD population. The design will provide preliminary evidence of feasibility, attrition, and satisfaction with treatment to design a definitive trial. If the trial is feasible, it opens up the possibility for interventions to target broader emotional processes in the precarious population with CVD and emotional distress.Trial registrationACTRN12615000555550, registered on 29/05/2015
from #Medicine via ola Kala on Inoreader http://ift.tt/1OJUFqJ
via IFTTT
Αρχειοθήκη ιστολογίου
-
►
2023
(138)
- ► Φεβρουαρίου (74)
- ► Ιανουαρίου (64)
-
►
2022
(849)
- ► Δεκεμβρίου (61)
- ► Σεπτεμβρίου (74)
- ► Φεβρουαρίου (65)
-
►
2021
(2936)
- ► Δεκεμβρίου (59)
- ► Σεπτεμβρίου (180)
- ► Φεβρουαρίου (325)
-
►
2020
(1624)
- ► Δεκεμβρίου (293)
- ► Σεπτεμβρίου (234)
- ► Φεβρουαρίου (28)
-
►
2019
(13362)
- ► Δεκεμβρίου (19)
- ► Σεπτεμβρίου (54)
- ► Φεβρουαρίου (5586)
- ► Ιανουαρίου (5696)
-
►
2018
(66471)
- ► Δεκεμβρίου (5242)
- ► Σεπτεμβρίου (5478)
- ► Φεβρουαρίου (4835)
- ► Ιανουαρίου (5592)
-
►
2017
(44259)
- ► Δεκεμβρίου (5110)
- ► Σεπτεμβρίου (5105)
-
▼
2016
(7467)
- ► Δεκεμβρίου (514)
- ► Σεπτεμβρίου (1038)
- ► Φεβρουαρίου (793)
-
▼
Ιανουαρίου
(578)
-
▼
Ιαν 11
(30)
- Epidemiology of hepatitis B and hepatitis C infect...
- Symptoms of anxiety and depression are frequent in...
- Liver metastasis from hepatoid adenocarcinoma of t...
- Pre-operative versus post-operative docetaxel-cisp...
- The preoperative SUVmax for 18F-FDG uptake predict...
- Clinical comparison of laparoscopy vs open surgery...
- All-cause mortality and progression risks to hepat...
- Bacteria exposed biliary epithelium and liver B ce...
- No increased mortality in 109,000 first-degree rel...
- Feasibility of total gastrectomy with D2 lymphaden...
- Alpha-synuclein in gastric and colonic mucosa in P...
- The adverse effect of tobacco smoking on the natur...
- Long-term outcome and need of re-operation in gast...
- The Royal Free Hospital-Nutritional Prioritizing T...
- Primary sclerosing cholangitis associated with inf...
- Lispro insulin in people with non-alcoholic liver ...
- Patients with Barrett’s esophagus and persistent l...
- Gut homing molecule regulation of the pathogenesis...
- Peginterferon lambda for the treatment of HBeAg-po...
- Electrochemical hydrogen sulfide biosensors
- Cardiovascular Health in Anxiety or Mood Problems ...
- Comparison of Serum MicroRNA21 and Tumor Markers i...
- The identity of the South African toad Sclerophrys...
- Non-native species in the vascular flora of highla...
- Rates and modes of body size evolution in early ca...
- Occurrence of ferredoxin:NAD+ oxidoreductase activ...
- Convex-hull mass estimates of the dodo (Raphus cuc...
- Advances and Controversies in Perioperative Airway...
- Gender-Specific Association of ATP2B1 Variants wit...
- Characteristics of Salmonella spp. Isolated from W...
-
▼
Ιαν 11
(30)
Αναζήτηση αυτού του ιστολογίου
Δευτέρα 11 Ιανουαρίου 2016
Cardiovascular Health in Anxiety or Mood Problems Study (CHAMPS): study protocol for a randomized controlled trial
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Αλέξανδρος Γ. Σφακιανάκης Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,0030693260717...
-
heory of COVID-19 pathogenesis Publication date: November 2020Source: Medical Hypotheses, Volume 144Author(s): Yuichiro J. Suzuki ScienceD...
-
Alimentary Pharmacology &Therapeutics, EarlyView. https://ift.tt/2qECBIJ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.